^
NTRK1 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
BRAF V600E
Neurofibrosarcoma
vemurafenib
Sensitive: C1 - Off-label
NF2 E108X
Neurofibrosarcoma
everolimus
Resistant: C3 – Early Trials
NF2 E108X
Neurofibrosarcoma
temsirolimus
Sensitive: C3 – Early Trials
TSC2 A736V
Neurofibrosarcoma
everolimus
Resistant: C3 – Early Trials
TSC2 A736V
Neurofibrosarcoma
temsirolimus
Sensitive: C3 – Early Trials
TJP1-ROS1 fusion + NF1 mutation
Neurofibrosarcoma
crizotinib
Resistant: C4 – Case Studies
NF1 mutation
Neurofibrosarcoma
DR6MP + JHU395
Sensitive: D – Preclinical
NF1 mutation
Neurofibrosarcoma
DR6MP
Sensitive: D – Preclinical
NF1 mutation
Neurofibrosarcoma
MEK inhibitor + c-MET inhibitor
Sensitive: D – Preclinical